scholarly journals QT dispersion in irritable bowel syndrome

2019 ◽  
Vol 7 (7) ◽  
pp. 2728
Author(s):  
Perihan Varim ◽  
Cengiz Karacaer ◽  
Ceyhun Varim ◽  
Selcuk Yaylaci ◽  
Mehmet Bulent Vatan
Keyword(s):  
Nervous System ◽  
Irritable Bowel Syndrome ◽  
Qt Dispersion ◽  
Newly Diagnosed ◽  
Mean Values ◽  
Control Subjects ◽  
Well Differentiated ◽  
Irritable Bowel ◽  
And Control ◽  
Electrocardiogram Ecg

Background: The pathogenesis of irritable bowel syndrome (IBS) has not been fully elucidated. The gastrointestinal tract have a well-differentiated intrinsic nervous system and also this system is connected with nervous system. The symptoms of IBS are related with autonomic nervous system (ANS). It was also possible to see cardiovascular symptoms due to this link. This link can influence QT dispersion (QTd). The aim of this case control study is to show the cardiac effects of IBS by changes in QTd.Methods: There were 56 newly diagnosed patients with IBS and 60 control subjects were included in this study. IBS was diagnosed using the new Roma IV Criterias. Standard 12-lead electrocardiogram (ECG) were taken in both two groups. QTd and corrected QTd (QTcd), QT max, QT min, QT avarage, Corrected QT (QTc) min, QTc max, QTc avarage values were calculated with Bazzet Formula from rest ECGs.Results: There were 56 newly diagnosed patients with IBS and 60 control subjects were included in the study (p:0.94). The mean age of the patients and control patients were 51.75±10.41 years and 48.41±9.72 (p: 0.53) years, respectively. QTd and corrected QTd (QTcd), QT max, QT min, QT mean, Corrected QT (QTc) min, QTc max, QTc mean values were calculated. QTd and QTcd values were found to be significantly higher in the patients with IBS (40.2±7.18; 34.1±6.18 / 52±9.8; 50.6±7.61 Msec, respectively). It is concluded that, QTd (p: 0.022) and QTcd (p: 0.032) were significantly incresased in the IBS.Conclusions: Activation of ANS in the patients with IBS can affect QT period in ECG.

Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention

2000 ◽  
Vol 118 (5) ◽  
pp. 842-848 ◽  
Author(s):  
Howard Mertz ◽  
Victoria Morgan ◽  
Gordon Tanner ◽  
David Pickens ◽  
Ronald Price ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cerebral Activation ◽  
Control Subjects ◽  
Irritable Bowel ◽  
And Control ◽  
Rectal Distention

scholarly journals Blastocystis Is Associated with Decrease of Fecal Microbiota Protective Bacteria: Comparative Analysis between Patients with Irritable Bowel Syndrome and Control Subjects

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e111868 ◽  
Author(s):  
Céline Nourrisson ◽  
Julien Scanzi ◽  
Bruno Pereira ◽  
Christina NkoudMongo ◽  
Ivan Wawrzyniak ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Comparative Analysis ◽  
Fecal Microbiota ◽  
Control Subjects ◽  
Irritable Bowel ◽  
And Control

Cerebral Activation in Patients With Irritable Bowel Syndrome and Control Subjects During Rectosigmoid Stimulation

2001 ◽  
Vol 63 (3) ◽  
pp. 365-375 ◽  
Author(s):  
Bruce D. Naliboff ◽  
Stuart W. G. Derbyshire ◽  
Julie Munakata ◽  
Steve Berman ◽  
Mark Mandelkern ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cerebral Activation ◽  
Control Subjects ◽  
Irritable Bowel ◽  
And Control

scholarly journals The fecal mycobiome in patients with Irritable Bowel Syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
A. Das ◽  
E. O’Herlihy ◽  
F. Shanahan ◽  
P. W. O’Toole ◽  
I. B. Jeffery
Keyword(s):  
Irritable Bowel Syndrome ◽  
Dietary Habits ◽  
Bile Acid Malabsorption ◽  
Operational Taxonomic Units ◽  
Control Subjects ◽  
Diagnostic Potential ◽  
Unknown Species ◽  
Irritable Bowel ◽  
And Control ◽  
Better Than

AbstractAlterations of the gut microbiota have been reported in various gastrointestinal disorders, but knowledge of the mycobiome is limited. We investigated the gut mycobiome of 80 patients with Irritable Bowel Syndrome (IBS) in comparison with 64 control subjects. The fungal-specific internal transcribed spacer 1 (ITS-1) amplicon was sequenced, and mycobiome zero-radius operational taxonomic units (zOTUs) were defined representing known and unknown species and strains. The fungal community was sparse and individual-specific in all (both IBS and control) subjects. Although beta-diversity differed significantly between IBS and controls, no difference was found among clinical subtypes of IBS or in comparison with the mycobiome of subjects with bile acid malabsorption (BAM), a condition which may overlap with IBS with diarrhoea. The mycobiome alterations co-varied significantly with the bacteriome and metabolome but were not linked with dietary habits. As a putative biomarker of IBS, the predictive power of the fecal mycobiome in machine learning models was significantly better than random but insufficient for clinical diagnosis. The mycobiome presents limited therapeutic and diagnostic potential for IBS, despite co-variation with bacterial components which do offer such potential.

Differences in productivity QOL, and resource use in newly diagnosed and established irritable bowel syndrome (IBS) patients

2001 ◽  
Vol 120 (5) ◽  
pp. A634-A634
Author(s):  
P JHINGRAN ◽  
J RICCI ◽  
M MARKOWITZ ◽  
S GORDON ◽  
A ASGHARIAN ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Resource Use ◽  
Newly Diagnosed ◽  
Irritable Bowel

scholarly journals The Prevalence of Anti-Zein Antibodies: A Comparative Study between Celiac Disease and Irritable Bowel Syndrome

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 649
Author(s):  
Luis Alberto Sánchez-Vargas ◽  
Karina Guadalupe Hernández-Flores ◽  
Francisco Javier Cabrera-Jorge ◽  
José María Remes-Troche ◽  
Job Reyes-Huerta ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Celiac Disease ◽  
Gastrointestinal Disorder ◽  
Newly Diagnosed ◽  
Disease Group ◽  
Immune Mediated ◽  
Healthy Control ◽  
Gliadin Peptides ◽  
Irritable Bowel ◽  
First Time

Celiac disease (CD) is a chronic immune-mediated enteropathy triggered by exposure to dietary gluten in genetically predisposed individuals. In contrast, irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting the large intestine, without an autoimmune component. Here, we evaluated the prevalence of IgA and IgG antibodies to maize zeins (AZA) in patients with CD and IBS. Using an in-house ELISA assay, the IgA and IgG anti-zein antibodies in the serum of 37 newly diagnosed CD (16 biopsy proved and 21 serological diagnosis) and 375 IBS patients or 302 healthy control (HC) subjects were measured. Elevated levels of IgA AZA were found in CD patients compared with IBS patients (p < 0.01) and HC (p < 0.05). CD patients had the highest prevalence (35.1%), followed by IBS (4.3%) and HCs (2.3%) (p < 0.0001). IgG AZA antibodies were not found in any CD patients, IBS patients, or HC subjects. A significant positive correlation was found between IgA AZA with IgA anti-gliadin (AGA, r = 0.34, p < 0.01) and IgA anti-deaminated gliadin peptides (DGP, r = 0.42, p < 0.001) in the celiac disease group. Taken together, our results show for the first time a higher prevalence of AZA IgA antibodies in newly diagnosed CD patients than in IBS patients, confirming a biased immune response to other gliadin-related prolamins such as maize zeins in genetically susceptible individuals.

scholarly journals Reduced Serum Adiponectin Levels in Type 2 Diabetic Patients in Zaria

2018 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Serum Adiponectin ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Mean Values ◽  
Control Subjects ◽  
Type 2 Dm ◽  
And Control ◽  
Biochemical Assessment ◽  
Type 2 Diabetic

Background: Adiponectin is a collagen-like plasma protein secreted by adipocytes that has been suggested to play a causal role in the development of insulin resistance. Even though hypoadiponectinaemia is reported to be closely associated with obesity-related diseases such as ACVD, type 2 DM, dyslipidaemia, report from our environment is lacking. Materials and Methods: Serum adiponectin, insulin and glucose were measured in 90 type 2 diabetic and control subjects respectively. The patients were known diabetics attending the diabetic clinic at the ABUTH, Zaria. The control subjects were apparently healthy individuals within the hospital and Zaria environs. Results: Mean serum adiponectin levels were significantly lower (P<0.05) in the diabetic patients than in the control subjects. On the other hand, the mean values of insulin and glucose were significantly higher (P<0.05) in the diabetic patients than in the controls. Conclusion: Measurement of serum adiponectin as an adjunct in the biochemical assessment of type 2 DM is suggested.

scholarly journals Rational Use of Fecal Calprotectin in Irritable Bowel Syndrome and Inflammatory Bowel Disease

2021 ◽  
Author(s):  
Roberto Catanzaro ◽  
Alfio Maugeri ◽  
Morena Sciuto ◽  
Fang He ◽  
Baskar Balakrishnan ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Gastrointestinal Disorder ◽  
Fecal Calprotectin ◽  
Mean Values ◽  
Inflammatory Bowel ◽  
Irritable Bowel

The gastrointestinal pathologies have increased over the last years. The clinical pictures of inflammatory and irritable bowel disease might overlap, leading to expensive and invasive tests. Our study aims to investigate fecal calprotectin as an effective tool for differential diagnosis of gastrointestinal disorders. Two hundred fifty-six patients with the diagnosis of the gastrointestinal disorder and subjected to colonoscopy were collected for the statistical analysis of fecal calprotectin. The differential diagnosis of intestinal inflammation or non-inflammation was performed according to the Receiver Operating Characteristic (ROC) curve that outlines the Area Under Curve (AUC), Sensitivity (Se), Specificity (Sp). Fecal calprotectin was significantly elevated in patients with inflammatory bowel disease compared with patients with irritable bowel syndrome. Especially, the mean values of fecal calprotectin were 522 g/g (IQR=215-975) and 21 g/g (IQR=14-34.5) in patients with and without inflammation, respectively (P<0.0001). AUC value of fecal calprotectin was 0.958 (Se=88.9%, Sp=91.1%, with a cut-off value of 50 g/g) for differentiating between inflammatory bowel disease and irritable bowel syndrome. Fecal calprotectin seems to be a non-invasive and inexpensive biomarker useful for the purpose of a differential diagnosis between inflammatory bowel disease and irritable bowel syndrome.

Sign in / Sign up

Export Citation Format

Share Document